NCT02130635 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 18, 2015

Study Completion Date

August 18, 2015

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK2269557 100 MCG

100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

DRUG

GSK2269557 500 MCG

500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device

DRUG

PLACEBO

Lactose administered using a matching dry powder inhaler device

Trial Locations (2)

GSK Investigational Site, Berlin

GSK Investigational Site, Großhansdorf